The Public Record
Thomas Harold Massie is an American politician serving as the U.S. Representative for Kentucky's 4th congressional district since 2013. A member of the Republican Party, Massie has been an advocate for limited government and individual liberties. He is known for his libertarian-leaning views and has often focused on issues such as fiscal responsibility and government transparency. Throughout his tenure, he has been involved in various legislative efforts and has made headlines for his outspoken positions on a range of topics.
So the copay, because of the way the pharmacy benefit managers work and the other intermediaries, the copay that my constituents see, or the check that they have to write out, or sometimes they have to borrow the money for that copay, that…
The U.S. Congress shall have power to promote the progress of science and useful arts by securing, for limited times, to authors and inventors the exclusive right to their respective writings and discoveries.
That is 20 years from when the invention occurs, and like you said sometimes you are only left with a few years to try and recoup the investment.
If companies couldn't recover their cost? That should be a fairly simple question to answer.
It feels like to me, just in closing, we need some kind of truth in pricing here.
Is there something that we can do in Congress to make it easier to get to a generic label from a brand name label after a drug goes off the patent?
The FDA's rigorous process is a huge reason why so many Americans trust that the medications and the vaccines that come to market are safe and dependable.
I do wish that my friends on the other side of the aisle, if they were serious about true reform and lowering prices we would be looking at something like H.R. 19 instead of pushing something like H.R. 3.
The Congressional Budget Office said that it would result in 38 fewer cures over the next 20 years.
We just simply cannot go down that path of eliminating any potential cure for some of these serious diseases.
H.R. 3 really would completely gut the pharmaceutical innovations which we all so desperately need and we rely upon.
We don't need to have cures that could potentially come in the market not coming to the market.
This is according to the CBO, and they confirmed that there would be a loss of cures available on the market.
Policies that incentivize investment in pharmaceutical innovation is a good thing, and that is where we need to be focused.
Democrats have chosen to discard months of bipartisan work and conduct this partisan hearing to attack companies that are working to help the American people.
Biopharmaceutical companies are far outspending the Federal Government for R&D for cures for various diseases.
I hope that members of this committee are aware that the U.S. Government ceases to be funded on September 30 of this year.
I ask unanimous consent to submit into the record two press releases from the U.S. Post Office.
In March, Speaker Pelosi called me a dangerous nuisance for insisting that at least half of Congress come back to vote on a $2 trillion bailout bill. This week, she has called Congress into session to vote on a post office bill that is…
My mail, if I send it to my neighbor, goes to Charleston, West Virginia, before it comes back to Kentucky. Is this part of some vast conspiracy? No. It's part of a decade's long realignment process where the post office is trying to match…
How many buffalo or bison were there in North America before Europeans settled it?
Then how can you make a statement that cattle, domestic cattle, produce more methane than the buffalo did before we got here? Because that statement is false.
Is there more methane produced by animals, ruminating animals in North America, than there was before we industrialized it and before we colonized it?
I was interested, particularly, in the climate-induced mortality risk impact of an increase in temperature.
Politicians like Thomas Massie
